ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

BACKGROUND: Data from phase 3 trials have demonstrated the efficacy and safety of benralizumab in patients with severe eosinophilic asthma (SEA). We conducted a real-world study examining the baseline characteristics of a large SEA population treated with benralizumab in clinical practice and assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzella, Francesco, Bargagli, Elena, Aliani, Maria, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, Del Giacco, Stefano, De Michele, Fausto, Di Marco, Fabiano, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Vultaggio, Alessandra, Simoni, Lucia, Ori, Alessandra, Boarino, Silvia, Vitiello, Gianfranco, Altieri, Elena, Canonica, Giorgio Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858449/
https://www.ncbi.nlm.nih.gov/pubmed/35183167
http://dx.doi.org/10.1186/s12931-022-01952-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858449/
https://www.ncbi.nlm.nih.gov/pubmed/35183167
http://dx.doi.org/10.1186/s12931-022-01952-8

Ejemplares similares